HUE054272T2 - Összetételek és módszerek az argináz-tevékenység gátlásához - Google Patents
Összetételek és módszerek az argináz-tevékenység gátlásáhozInfo
- Publication number
- HUE054272T2 HUE054272T2 HUE17829574A HUE17829574A HUE054272T2 HU E054272 T2 HUE054272 T2 HU E054272T2 HU E17829574 A HUE17829574 A HU E17829574A HU E17829574 A HUE17829574 A HU E17829574A HU E054272 T2 HUE054272 T2 HU E054272T2
- Authority
- HU
- Hungary
- Prior art keywords
- compositions
- methods
- arginase activity
- inhibiting arginase
- inhibiting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662438092P | 2016-12-22 | 2016-12-22 | |
| US201662439614P | 2016-12-28 | 2016-12-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE054272T2 true HUE054272T2 (hu) | 2021-09-28 |
Family
ID=60972528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17829574A HUE054272T2 (hu) | 2016-12-22 | 2017-12-22 | Összetételek és módszerek az argináz-tevékenység gátlásához |
Country Status (34)
| Country | Link |
|---|---|
| US (4) | US10287303B2 (https=) |
| EP (2) | EP3559009B1 (https=) |
| JP (2) | JP7018949B2 (https=) |
| KR (1) | KR102579849B1 (https=) |
| CN (2) | CN114989205A (https=) |
| AU (2) | AU2017382405B2 (https=) |
| BR (1) | BR112019012589B1 (https=) |
| CA (1) | CA3046987A1 (https=) |
| CL (1) | CL2019001711A1 (https=) |
| CO (1) | CO2019007839A2 (https=) |
| CR (1) | CR20190339A (https=) |
| CY (1) | CY1124483T1 (https=) |
| DK (2) | DK3842442T3 (https=) |
| EC (1) | ECSP19045511A (https=) |
| ES (2) | ES2970715T3 (https=) |
| HR (1) | HRP20210848T1 (https=) |
| HU (1) | HUE054272T2 (https=) |
| IL (2) | IL292677A (https=) |
| LT (1) | LT3559009T (https=) |
| MD (1) | MD3559009T2 (https=) |
| MX (2) | MX378460B (https=) |
| MY (1) | MY197478A (https=) |
| NZ (1) | NZ754364A (https=) |
| PE (1) | PE20191541A1 (https=) |
| PH (1) | PH12019501396A1 (https=) |
| PL (1) | PL3559009T3 (https=) |
| PT (1) | PT3559009T (https=) |
| RS (1) | RS61996B1 (https=) |
| SG (2) | SG10201911240PA (https=) |
| SI (1) | SI3559009T1 (https=) |
| SM (1) | SMT202100573T1 (https=) |
| TW (1) | TWI818902B (https=) |
| UA (1) | UA124711C2 (https=) |
| WO (1) | WO2018119440A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2632927T3 (en) | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| EP3365340B1 (en) | 2015-10-19 | 2022-08-10 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| US20170145025A1 (en) | 2015-11-19 | 2017-05-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2916874T3 (es) | 2015-12-17 | 2022-07-06 | Incyte Corp | Derivados de N-fenil-piridina-2-carboxamida y su uso como moduladores de la interacción proteína/proteína PD-1/PD-L1 |
| AU2016379372A1 (en) | 2015-12-22 | 2018-08-02 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| ES2906460T3 (es) | 2016-05-06 | 2022-04-18 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
| MA45669A (fr) | 2016-07-14 | 2019-05-22 | Incyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| EP3558990B1 (en) * | 2016-12-22 | 2022-08-10 | Incyte Corporation | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| AU2017382870B2 (en) | 2016-12-22 | 2022-03-24 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
| SMT202100573T1 (it) * | 2016-12-22 | 2021-11-12 | Calithera Biosciences Inc | Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| ES2874756T3 (es) | 2016-12-22 | 2021-11-05 | Incyte Corp | Derivados de triazolo[1,5-A]piridina como inmunomoduladores |
| CN108322295B (zh) | 2017-01-17 | 2021-12-24 | 维沃移动通信有限公司 | 一种边带信息的发送方法、接收方法、发送端和接收端 |
| TWI803574B (zh) | 2018-02-17 | 2023-06-01 | 瑞典商阿斯特捷利康公司 | 精胺酸酶抑制劑及其使用方法 |
| EP3774843B1 (en) | 2018-03-29 | 2022-05-25 | Molecure SA | Dipeptide piperidine derivatives |
| CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| WO2019217821A1 (en) | 2018-05-11 | 2019-11-14 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
| IL280924B2 (en) | 2018-08-22 | 2024-10-01 | Astrazeneca Ab | Arginase inhibitors and methods of use thereof |
| US12240867B2 (en) | 2018-12-18 | 2025-03-04 | Merck Sharp & Dohme Llc | Arginase inhibitors and methods of use |
| CN113395996B (zh) * | 2019-02-08 | 2024-05-28 | 阿斯利康(瑞典)有限公司 | 精氨酸酶抑制剂及其使用方法 |
| EP4010342A1 (en) | 2019-08-09 | 2022-06-15 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| WO2021067217A1 (en) | 2019-09-30 | 2021-04-08 | Incyte Corporation | Pyrido[3,2-d]pyrimidine compounds as immunomodulators |
| CN110759843A (zh) * | 2019-09-30 | 2020-02-07 | 东北师范大学 | 一种氟叠氮取代的四元杂环化合物的制备和应用 |
| CN110734456A (zh) * | 2019-11-06 | 2020-01-31 | 南京谷睿生物科技有限公司 | 一种化合物及其制备方法和医药上的应用 |
| BR112022009031A2 (pt) | 2019-11-11 | 2022-10-11 | Incyte Corp | Sais e formas cristalinas de um inibidor de pd-1/pd-l1 |
| WO2021257857A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Naphthyridinone compounds as jak2 v617f inhibitors |
| WO2021257863A1 (en) | 2020-06-19 | 2021-12-23 | Incyte Corporation | Pyrrolotriazine compounds as jak2 v617f inhibitors |
| US11767323B2 (en) | 2020-07-02 | 2023-09-26 | Incyte Corporation | Tricyclic pyridone compounds as JAK2 V617F inhibitors |
| SMT202500271T1 (it) | 2020-07-02 | 2025-09-12 | Incyte Corp | Composti di urea triciclici come inibitori di v617f di jak2 |
| US20220041630A1 (en) * | 2020-07-17 | 2022-02-10 | Incyte Corporation | Processes for the preparation of arginase inhibitors and their synthetic intermediates |
| US11661422B2 (en) | 2020-08-27 | 2023-05-30 | Incyte Corporation | Tricyclic urea compounds as JAK2 V617F inhibitors |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| US11866434B2 (en) | 2020-11-06 | 2024-01-09 | Incyte Corporation | Process for making a PD-1/PD-L1 inhibitor and salts and crystalline forms thereof |
| CN112387262B (zh) * | 2020-11-10 | 2021-12-07 | 泰州学院 | 一种基于光催化交联蛋白的手性固定相的制备方法、手性固定相及应用 |
| WO2022140231A1 (en) | 2020-12-21 | 2022-06-30 | Incyte Corporation | Deazaguaine compounds as jak2 v617f inhibitors |
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
| AR125273A1 (es) | 2021-02-25 | 2023-07-05 | Incyte Corp | Lactamas espirocíclicas como inhibidores de jak2 v617f |
| WO2023133505A2 (en) * | 2022-01-07 | 2023-07-13 | The Trustees Of Columbia University In The City Of New York | Inhibition of kynurenine synthesis and/or signaling to treat leukemia and myelodysplasia |
| CN119173514A (zh) | 2022-03-17 | 2024-12-20 | 因赛特公司 | 作为jak2 v617f抑制剂的三环脲化合物 |
| WO2024086273A1 (en) | 2022-10-21 | 2024-04-25 | Incyte Corporation | Tricyclic urea compounds as jak2 v617f inhibitors |
| TW202440086A (zh) | 2023-03-13 | 2024-10-16 | 美商英塞特公司 | 作為激酶抑制劑之雙環脲 |
| WO2026076207A1 (en) | 2024-10-04 | 2026-04-09 | Incyte Corporation | Tricyclic heteroaryl compounds as inhibitors of tyk2 and/or jak1 |
Family Cites Families (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4172896A (en) | 1978-06-05 | 1979-10-30 | Dainippon Pharmaceutical Co., Ltd. | Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same |
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| GB9217295D0 (en) | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
| US5358970A (en) | 1993-08-12 | 1994-10-25 | Burroughs Wellcome Co. | Pharmaceutical composition containing bupropion hydrochloride and a stabilizer |
| GB9315856D0 (en) | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
| US5541231A (en) | 1993-07-30 | 1996-07-30 | Glaxo Wellcome Inc. | Stabilized Pharmaceutical |
| DK0999825T3 (da) | 1997-07-29 | 2004-02-09 | Alcon Lab Inc | Oftalmiske sammensætninger indeholdende galactomannanpolymerer og borater |
| WO1999019295A1 (en) | 1997-10-10 | 1999-04-22 | Trustees Of The University Of Pennsylvania | Compositions and methods for inhibiting arginase activity |
| US6110973A (en) | 1998-01-29 | 2000-08-29 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US20040063666A1 (en) | 1998-10-09 | 2004-04-01 | David Christianson | Compositions for inhibiting arginase activity |
| US8889112B2 (en) | 1999-09-16 | 2014-11-18 | Ocularis Pharma, Llc | Ophthalmic formulations including selective alpha 1 antagonists |
| CA2901451C (en) | 2000-05-10 | 2020-04-07 | Moses Rodriguez | Human igm antibodies with the capability of inducing remyelination, and diagnostic and therapeutic uses thereof particularly in the central nervous system |
| JP2004502948A (ja) | 2000-07-06 | 2004-01-29 | ファル ダイアグノスティクス | アルギニン化合物の検出のための方法及びキット |
| CA2431080A1 (en) | 2003-06-02 | 2004-12-02 | Catherine Adele O'brien | Enhancement of anticancer immunity through inhibition of arginase |
| US6933289B2 (en) | 2003-07-01 | 2005-08-23 | Allergan, Inc. | Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| CA2534484A1 (en) | 2003-08-07 | 2005-02-17 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes and methods for making and using same |
| US20050059744A1 (en) | 2003-09-12 | 2005-03-17 | Allergan, Inc. | Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions |
| WO2007005620A2 (en) | 2005-07-01 | 2007-01-11 | The Johns Hopkins University | Arginase ii: a target treatment of aging heart and heart failure |
| US20070203140A1 (en) | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| US20080146624A1 (en) | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| ES2444574T3 (es) | 2006-09-19 | 2014-02-25 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
| WO2008036643A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080182882A1 (en) | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| EP2083812B1 (en) | 2006-11-21 | 2017-04-05 | Rijksuniversiteit Groningen | Use of arginase inhibitors in the treatment of asthma and allergic rhinitis |
| ME02372B (me) | 2006-11-22 | 2016-06-20 | Incyte Holdings Corp | Imidazotriazini i imidazopiramidini kao inhibitori kinaze |
| US20100189544A1 (en) | 2007-07-12 | 2010-07-29 | Sanyo Denki Co., Ltd. | Counter-rotating axial-flow fan |
| JP5421272B2 (ja) | 2007-10-12 | 2014-02-19 | リゾルヴィクス・ファーマシューティカルズ・インコーポレイテッド | 眼病治療のための組成物及び方法 |
| JP5583592B2 (ja) | 2007-11-30 | 2014-09-03 | ニューリンク ジェネティクス コーポレイション | Ｉｄｏ阻害剤 |
| JP2011518841A (ja) | 2008-04-24 | 2011-06-30 | ニューリンク ジェネティクス， インコーポレイテッド | Ｉｄｏ阻害剤 |
| JP2011519868A (ja) | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | 癌を処置するための化学療法剤の連続投与 |
| PL2315756T3 (pl) | 2008-07-08 | 2015-02-27 | Incyte Holdings Corp | 1,2,5-oksadiazole jako inhibitory 2,3-dioksygenazy indoloaminy |
| SI2389352T1 (sl) | 2009-01-26 | 2019-08-30 | The Trustees Of The University Of Pennsylvania, Center For Technology Transfer | Inhibitorji arginaze in postopki uporabe |
| US8987315B2 (en) | 2009-12-31 | 2015-03-24 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| EP2547366A4 (en) | 2010-03-18 | 2013-08-07 | Univ Colorado State Res Found | SUPPRESSOR CELL HEMMER OBTAINED FROM MYELOID CELLS |
| CN103068830B (zh) | 2010-04-22 | 2016-06-29 | 马尔斯公司 | 精氨酸酶抑制剂及其治疗应用 |
| AU2011242562B2 (en) | 2010-04-24 | 2016-10-13 | Mycovia Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| CA2807546C (en) * | 2010-08-10 | 2022-08-23 | Rempex Pharmaceuticals, Inc. | Cyclic boronic acid ester derivatives and therapeutic uses thereof |
| WO2012025186A1 (en) | 2010-08-27 | 2012-03-01 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| DK2632927T3 (en) * | 2010-10-26 | 2016-04-11 | Mars Inc | Boronates AS ARGINSASEINHIBITORER |
| US9056855B2 (en) | 2010-10-28 | 2015-06-16 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| EP3483147A1 (en) | 2010-11-13 | 2019-05-15 | Innocrin Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| EA201390876A1 (ru) | 2010-12-13 | 2013-12-30 | Вайамет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| CA2824599C (en) | 2010-12-31 | 2020-03-10 | Astrazeneca Uk Limited | Arginase inhibitors and methods of use thereof |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| WO2012177635A1 (en) | 2011-06-19 | 2012-12-27 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| IN2014MN00093A (https=) | 2011-06-19 | 2015-06-19 | Viamet Pharmaceuticals Inc | |
| EA025266B1 (ru) | 2011-06-23 | 2016-12-30 | Ваймет Фармасьютикалс, Инк. | Соединения, ингибирующие металлоферменты |
| JP2014525442A (ja) | 2011-08-30 | 2014-09-29 | ヴィアメット ファーマスーティカルズ，インコーポレイテッド | 金属酵素阻害化合物 |
| US9266908B2 (en) | 2011-10-19 | 2016-02-23 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| RU2014120166A (ru) * | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | Замещенные бициклические аза-гетероциклы и их аналоги в качестве модуляторов сиртуина |
| EP3351541A1 (en) | 2011-12-11 | 2018-07-25 | Viamet Pharmaceuticals (NC), Inc. | Metalloenzyme inhibitor compounds |
| ES2774267T3 (es) | 2012-01-20 | 2020-07-20 | Mycovia Pharmaceuticals Inc | Compuestos inhibidores de metaloenzimas |
| EP2807161B1 (en) | 2012-01-28 | 2017-10-04 | Merck Patent GmbH | Triazolo[4,5-d]pyrimidine derivatives |
| CA2863723C (en) | 2012-02-21 | 2020-09-22 | Carl Deutsch | 8-substituted 2-amino-[1,2,4]triazolo[1,5-a]pyrazines as syk tryrosine kinase inhibitors and gcn2 serin kinase inhibitors |
| ES2552518T3 (es) | 2012-02-21 | 2015-11-30 | Merck Patent Gmbh | Derivados cíclicos de diaminopiridina como inhibidores de Syk |
| WO2013131609A1 (en) | 2012-03-07 | 2013-09-12 | Merck Patent Gmbh | Triazolopyrazine derivatives |
| CA2870526C (en) * | 2012-04-18 | 2020-05-05 | Mars, Incorporated | Ring constrained analogs as arginase inhibitors |
| ES2618004T3 (es) | 2012-08-07 | 2017-06-20 | Merck Patent Gmbh | Derivados de piridopirimidina como inhibidores de proteínas quinasas |
| US20150246898A1 (en) | 2012-09-12 | 2015-09-03 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds |
| SG11201503459SA (en) | 2012-11-02 | 2015-06-29 | Pharmacyclics Inc | Tec family kinase inhibitor adjuvant therapy |
| EP2948450A4 (en) | 2013-01-28 | 2016-11-09 | Viamet Pharmaceuticals Inc | METALLOENZYMINHIBITORVERBINDUNGEN |
| AU2014224975B2 (en) | 2013-03-05 | 2017-09-14 | Merck Patent Gmbh | Triazolo(4,5-d)pyrimidine derivatives for the treatment of diseases such as cancer |
| AU2014224976B2 (en) | 2013-03-05 | 2017-09-28 | Merck Patent Gmbh | 9-(aryl or heteroaryl)-2-(pyrazolyl, pyrrolidinyl or cyclopentyl)aminopurine derivatives as anticancer agents |
| WO2014141110A2 (en) | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
| CN105209449B (zh) | 2013-03-14 | 2019-02-01 | 库拉德夫制药私人有限公司 | 犬尿氨酸途径的抑制剂 |
| SG11201507255QA (en) | 2013-03-14 | 2015-10-29 | Newlink Genetics Corp | Tricyclic compounds as inhibitors of immunosuppression mediated by tryptophan metabolization |
| SG11201506920QA (en) | 2013-03-15 | 2015-09-29 | Bristol Myers Squibb Co | Ido inhibitors |
| RS57462B1 (sr) | 2013-03-15 | 2018-09-28 | Bristol Myers Squibb Co | Inhibitori indolamin 2,3-dioksigenaze (ido) |
| CN105164136B (zh) | 2013-05-06 | 2017-12-22 | 默克专利股份公司 | 作为激酶抑制剂的大环化合物 |
| HK1223093A1 (zh) | 2013-05-28 | 2017-07-21 | Viamet Pharmaceuticals (NC), Inc. | 杀真菌组合物 |
| EA029126B1 (ru) | 2013-07-01 | 2018-02-28 | Бристол-Майерс Сквибб Компани | Ингибиторы ido |
| ES2707961T3 (es) | 2013-07-11 | 2019-04-08 | Bristol Myers Squibb Co | Inhibidores de IDO |
| US10821178B2 (en) | 2013-07-29 | 2020-11-03 | Board Of Regents Of The University Of Nebraska | Methods of treating biofilm infections comprising administering inhibitors of myeloid-derived suppressor cells |
| CA2921199A1 (en) | 2013-08-27 | 2015-03-05 | Bristol-Myers Squibb Company | Ido inhibitors |
| JP6508785B2 (ja) | 2013-10-25 | 2019-05-08 | ファーマサイクリックス エルエルシー | ブルトンチロシンキナーゼ阻害剤および免疫療法を使用する処置 |
| DK3066085T3 (da) | 2013-11-08 | 2020-06-02 | Incyte Holdings Corp | Fremgangsmåde til syntesen af en indolamin-2,3-dioxygenaseinhibitor |
| US20170037125A1 (en) | 2014-02-04 | 2017-02-09 | Incyte Corporation | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| US9944664B2 (en) | 2014-04-15 | 2018-04-17 | Dow Agrosciences Llc | Metalloenzyme inhibitor compounds as fungicides |
| JP6532480B2 (ja) | 2014-04-15 | 2019-06-19 | ダウ アグロサイエンシィズ エルエルシー | 殺真菌剤としての金属酵素阻害剤化合物 |
| CN106535884A (zh) | 2014-06-06 | 2017-03-22 | 弗雷克萨斯生物科学公司 | 免疫调节剂 |
| TW201619133A (zh) | 2014-08-21 | 2016-06-01 | 裘拉德製藥私人有限公司 | 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物 |
| SG10201804868PA (en) | 2014-09-05 | 2018-07-30 | Merck Patent Gmbh | Compounds for the inhibition of indoleamine-2,3-dioxygenase |
| CN105879030A (zh) | 2014-09-30 | 2016-08-24 | 复旦大学 | 治疗肿瘤的增效药物复合物及其制备方法 |
| GB201417369D0 (en) | 2014-10-01 | 2014-11-12 | Redx Pharma Ltd | Compounds |
| WO2016057986A1 (en) | 2014-10-10 | 2016-04-14 | The Trustees Of Columbia University In The City Of New York | Tandem epitope constructs for presentation of cd4 and cd8 epitopes and uses thereof |
| GB201418300D0 (en) | 2014-10-15 | 2014-11-26 | Redx Pharma Ltd | Compounds |
| MX2017005462A (es) | 2014-11-05 | 2017-07-28 | Flexus Biosciences Inc | Agentes inmunorreguladores. |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| UY36391A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| CN107405404A (zh) | 2015-03-20 | 2017-11-28 | 塞米·欧尤·奥皮约 | 苏拉明和精氨酸酶抑制剂在恶性肿瘤中的用途 |
| KR20170134980A (ko) | 2015-04-03 | 2017-12-07 | 브리스톨-마이어스 스큅 컴퍼니 | 암의 치료를 위한 인돌아민-2,3-디옥시게나제의 억제제 |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| US10945994B2 (en) | 2015-05-14 | 2021-03-16 | Pfizer Inc. | Combinations comprising a pyrrolidine-2,5-dione IDO1 inhibitor and an anti-body |
| WO2016196890A1 (en) | 2015-06-04 | 2016-12-08 | Vtv Therapeutics Llc | Inhibitors of hexokinase and methods of use thereof |
| KR20180021117A (ko) | 2015-06-23 | 2018-02-28 | 칼리테라 바이오사이언시즈, 인코포레이티드 | 아르기나제 활성 억제를 위한 조성물 및 방법 |
| WO2017075363A1 (en) * | 2015-10-30 | 2017-05-04 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
| PL417066A1 (pl) | 2016-05-04 | 2017-11-06 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| SMT202100573T1 (it) * | 2016-12-22 | 2021-11-12 | Calithera Biosciences Inc | Composizioni e metodi per l'inibizione dell'attivita' dell'arginasi |
| WO2018209290A1 (en) | 2017-05-12 | 2018-11-15 | Calithera Biosciences, Inc. | Method of preparing (3r,4s)-3-acetamido-4-allyl-n-(tert-butyl)pyrrolidine-3-carboxamide |
-
2017
- 2017-12-22 SM SM20210573T patent/SMT202100573T1/it unknown
- 2017-12-22 BR BR112019012589-2A patent/BR112019012589B1/pt not_active IP Right Cessation
- 2017-12-22 CN CN202210836886.8A patent/CN114989205A/zh active Pending
- 2017-12-22 IL IL292677A patent/IL292677A/en unknown
- 2017-12-22 SG SG10201911240PA patent/SG10201911240PA/en unknown
- 2017-12-22 UA UAA201908476A patent/UA124711C2/uk unknown
- 2017-12-22 NZ NZ754364A patent/NZ754364A/en not_active IP Right Cessation
- 2017-12-22 MD MDE20191232T patent/MD3559009T2/ro unknown
- 2017-12-22 SI SI201730835T patent/SI3559009T1/sl unknown
- 2017-12-22 PE PE2019001311A patent/PE20191541A1/es unknown
- 2017-12-22 PT PT178295747T patent/PT3559009T/pt unknown
- 2017-12-22 KR KR1020197021468A patent/KR102579849B1/ko active Active
- 2017-12-22 US US15/853,310 patent/US10287303B2/en active Active
- 2017-12-22 MY MYPI2019003368A patent/MY197478A/en unknown
- 2017-12-22 DK DK21158664.9T patent/DK3842442T3/da active
- 2017-12-22 TW TW106145440A patent/TWI818902B/zh active
- 2017-12-22 CN CN201780080358.1A patent/CN110382508B/zh active Active
- 2017-12-22 JP JP2019534159A patent/JP7018949B2/ja active Active
- 2017-12-22 MX MX2019007471A patent/MX378460B/es unknown
- 2017-12-22 WO PCT/US2017/068307 patent/WO2018119440A1/en not_active Ceased
- 2017-12-22 CA CA3046987A patent/CA3046987A1/en active Pending
- 2017-12-22 SG SG10201911243WA patent/SG10201911243WA/en unknown
- 2017-12-22 RS RS20210763A patent/RS61996B1/sr unknown
- 2017-12-22 ES ES21158664T patent/ES2970715T3/es active Active
- 2017-12-22 HU HUE17829574A patent/HUE054272T2/hu unknown
- 2017-12-22 HR HRP20210848TT patent/HRP20210848T1/hr unknown
- 2017-12-22 LT LTEP17829574.7T patent/LT3559009T/lt unknown
- 2017-12-22 DK DK17829574.7T patent/DK3559009T3/da active
- 2017-12-22 EP EP17829574.7A patent/EP3559009B1/en active Active
- 2017-12-22 AU AU2017382405A patent/AU2017382405B2/en not_active Ceased
- 2017-12-22 ES ES17829574T patent/ES2881395T3/es active Active
- 2017-12-22 EP EP21158664.9A patent/EP3842442B1/en active Active
- 2017-12-22 CR CR20190339A patent/CR20190339A/es unknown
- 2017-12-22 PL PL17829574T patent/PL3559009T3/pl unknown
-
2019
- 2019-03-29 US US16/370,857 patent/US10597411B2/en not_active Expired - Fee Related
- 2019-06-18 PH PH12019501396A patent/PH12019501396A1/en unknown
- 2019-06-19 CL CL2019001711A patent/CL2019001711A1/es unknown
- 2019-06-20 IL IL267532A patent/IL267532B/en unknown
- 2019-06-20 MX MX2020013649A patent/MX2020013649A/es unknown
- 2019-06-26 EC ECSENADI201945511A patent/ECSP19045511A/es unknown
- 2019-07-22 CO CONC2019/0007839A patent/CO2019007839A2/es unknown
-
2020
- 2020-02-14 US US16/792,186 patent/US11021495B2/en active Active
-
2021
- 2021-01-20 US US17/153,804 patent/US12054501B2/en active Active
- 2021-07-05 CY CY20211100602T patent/CY1124483T1/el unknown
-
2022
- 2022-02-01 JP JP2022014021A patent/JP2022066199A/ja not_active Abandoned
- 2022-02-17 AU AU2022201072A patent/AU2022201072A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE054272T2 (hu) | Összetételek és módszerek az argináz-tevékenység gátlásához | |
| IL288225A (en) | Preparations and methods for preventing arginase activity | |
| HUE063026T2 (hu) | Eljárások és készítmények LDHA expressziójának gátlására | |
| ZA201800328B (en) | Compositions and methods for inhibiting arginase activity | |
| IL254734B1 (en) | Modified t cells and methods of making and using the same | |
| HUE059788T2 (hu) | PD-1 elleni antitestek és készítmények | |
| HUE054159T2 (hu) | HPK1 gátlók és azok alkalmazási módja | |
| HUE046756T2 (hu) | Benzoxazepin-oxazolidinon vegyületek és azok alkalmazási módszerei | |
| HUE039869T2 (hu) | N-Azaspirocikloalkán helyettesített N-heteroaril vegyületek és készítmények az SHP2 aktivitás gátlására | |
| HUE052095T2 (hu) | Keratin kezelési készítmények és eljárások | |
| HUE055755T2 (hu) | Szulfonolkarmabidok és rokon vegyületeik valamint felhasználásuk | |
| DK3557998T3 (da) | Sammensætninger, kompositioner og anvendelsesmetoder | |
| PT3319612T (pt) | Oxisteróis e métodos de utilização dos mesmos | |
| IL258956A (en) | Compositions and methods for tumor transduction | |
| HUE055521T2 (hu) | Béta-nikotinát-észter nukleotidok és eljárás azok elõállítására | |
| IL257458B1 (en) | Dpep-1 binding compositions and methods of use | |
| EP3416483A4 (en) | CRYOPROTEKING COMPOSITIONS AND METHODS | |
| EP3277638A4 (en) | RETARD TABLET AND METHOD | |
| ES1116730Y (es) | Conjunto de soporte y proteccion de balizas de trenes. |